|
1
|
Xu Y, Wu G, Li J, Li J, Ruan N, Ma L, Han
X, Wei Y, Li L, Zhang H, et al: Screening and identification of key
biomarkers for bladder cancer: A study based on TCGA and GEO Data.
Biomed Res Int. 82(83401)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schlack K, Boegemann M, Steinestel J,
Schrader A and Krabbe L: The safety and efficacy of gemcitabine for
the treatment of bladder cancer. Expert Rev Anticancer Ther.
16:255–271. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shi S and Tian B: Identification of
biomarkers associated with progression and prognosis in bladder
cancer via co-expression analysis. Cancer Biomark. 24:183–193.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cao R, Yuan L, Ma B, Wang G, Qiu W and
Tian Y: An EMT-related gene signature for the prognosis of human
bladder cancer. J Cell Mol Med. 24:605–617. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Xie B, Wang S, Jiang N and Li JJ: Cyclin
B1/CDK1-regulated mitochondrial bioenergetics in cell cycle
progression and tumor resistance. Cancer Lett. 443:56–66.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Petrachkova T, Wortinger LA, Bard AJ,
Singh J, Warga R and Kane D: Lack of Cyclin B1 in zebrafish causes
lengthening of G2 and M phases. Dev Biol. 451:167–179.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Marques HP, da Silva SG, De Martin E,
Agopian VG and Martins PN: Emerging biomarkers in HCC patients:
Current status. Int J Surg. 82s:70–76. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang H, Zhang X, Li X, Meng WB, Bai ZT,
Rui SZ, Wang ZF, Zhou WC and Jin XD: Effect of CCNB1 silencing on
cell cycle, senescence, and apoptosis through the p53 signaling
pathway in pancreatic cancer. J Cell Physiol. 234:619–631.
2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fang Y, Yu H, Liang X, Xu J and Cai X:
Chk1-induced CCNB1 overexpression promotes cell proliferation and
tumor growth in human colorectal cancer. Cancer Biol Ther.
15:1268–1279. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zou Y, Ruan S, Jin L, Chen Z, Han H, Zhang
Y, Jian Z, Lin Y, Shi N and Jin H: CDK1, CCNB1, and CCNB2 are
prognostic biomarkers and correlated with immune infiltration in
hepatocellular carcinoma. Med Sci Monit. 26(e925289)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hu L, Pan X, Hu J, Zeng H, Liu X, Jiang M
and Jiang B: Proteasome inhibitors decrease paclitaxel-induced cell
death in nasopharyngeal carcinoma with the accumulation of
CDK1/cyclin B1. Int J Mol Med. 48(193)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zeng S, Yu X, Ma C, Song R, Zhang Z, Zi X,
Chen X, Wang Y, Yu Y, Zhao J, et al: Transcriptome sequencing
identifies ANLN as a promising prognostic biomarker in bladder
urothelial carcinoma. Sci Rep. 7(3151)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wu F, Sun Y, Chen J, Li H, Yao K, Liu Y,
Liu Q and Liu J: The oncogenic role of APC/C activator protein
Cdc20 by an integrated pan-cancer analysis in human tumors. Front
Oncol. 11(721797)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dobruch J and Oszczudłowski M: Bladder
cancer: Current challenges and future directions. Medicina
(Kaunas). 57(749)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jamasbi E, Hamelian M, Hossain MA and
Varmira K: The cell cycle, cancer development and therapy. Mol Biol
Rep. 49:10875–10883. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fang L, Du WW, Awan FM, Dong J and Yang
BB: The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex
suppressing cell invasion and tumorigenesis. Cancer Lett.
459:216–226. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chen EB, Qin X, Peng K, Li Q, Tang C, Wei
YC, Yu S, Gan L and Liu T: HnRNPR-CCNB1/CENPF axis contributes to
gastric cancer proliferation and metastasis. Aging (Albany NY).
11:7473–7491. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li Y, Ji S, Fu LY, Jiang T, Wu D and Meng
FD: Knockdown of cyclin-dependent kinase inhibitor 3 inhibits
proliferation and invasion in human gastric cancer cells. Oncol
Res. 25:721–731. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang X, Zhou S, Yang C, Cao C, He M and Zi
S: CCNB1, negatively regulated by miR-559, promotes the
proliferation, migration, and invasion of ovarian carcinoma cells.
Mol Biotechnol. 64:958–969. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gu J, Liu X, Li J and He Y: MicroRNA-144
inhibits cell proliferation, migration and invasion in human
hepatocellular carcinoma by targeting CCNB1. Cancer Cell Int.
19(15)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Song Y, Zhao C, Dong L, Fu M, Xue L, Huang
Z, Tong T, Zhou Z, Chen A, Yang Z, et al: Overexpression of cyclin
B1 in human esophageal squamous cell carcinoma cells induces tumor
cell invasive growth and metastasis. Carcinogenesis. 29:307–315.
2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sun J, Du Y, Song Q, Nan J, Guan PZ, Guo
JH, Wang X, Yang JB and Zhao CY: E2F is required for STAT3-mediated
upregulation of cyclin B1 and Cdc2 expressions and contributes to
G2-M phase transition. Acta Biochim Biophys Sin (Shanghai).
51:313–322. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pan XW, Chen L, Hong Y, Xu DF, Liu X, Li
L, Huang Y, Cui LM, Gan SS, Yang QW, et al: Cui: EIF3D silencing
suppresses renal cell carcinoma tumorigenesis via inducing G2/M
arrest through downregulation of Cyclin B1/CDK1 signaling. Int J
Oncol. 48:2580–2590. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lohberger B, Leithner A, Stuendl N,
Kaltenegger H, Kullich W and Steinecker-Frohnwieser B: Diacerein
retards cell growth of chondrosarcoma cells at the G2/M cell cycle
checkpoint via cyclin B1/CDK1 and CDK2 downregulation. BMC Cancer.
15(891)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ying Y, Wang Z, Tan Y, Cao H, Gao H, Zhang
Z, Zeng S and Xu C: Identification and validation of
immunohistochemical marker panels to predict the prognosis of
muscle invasive bladder cancer. Transl Androl Urol. 12:176–186.
2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liu D, Xu W, Ding X, Yang Y, Su B and Fei
K: Polymorphisms of CCNB1 associated with the clinical outcomes of
platinum-based chemotherapy in Chinese NSCLC Patients. J Cancer.
8:3785–3794. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu A, Zeng S, Lu X, Xiong Q, Xue Y, Tong
L, Xu W, Sun Y, Zhang Z and Xu C: Overexpression of G2 and S
phase-expressed-1 contributes to cell proliferation, migration, and
invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor
prognosis in bladder cancer. Int J Biol Macromol. 123:322–334.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen Q, Hu J, Deng J, Fu B and Guo J:
Bioinformatics analysis identified key molecular changes in bladder
cancer development and recurrence. Biomed Res Int.
16(3917982)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Brcic L, Heidinger M, Sever AZ, Zacharias
M, Jakopovic M, Fediuk M, Maier A, Quehenberger F, Seiwerth S and
Popper H: Prognostic value of cyclin A2 and B1 expression in lung
carcinoids. Pathology. 51:481–486. 2019.PubMed/NCBI View Article : Google Scholar
|
